Canada Life’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7,525
| Closed | -$23K | – | 2034 |
|
|
2024
Q4 | $23K | Hold |
7,525
| – | – | ﹤0.01% | 1952 |
|
|
2024
Q3 | $39K | Hold |
7,525
| – | – | ﹤0.01% | 1970 |
|
|
2024
Q2 | $19K | Hold |
7,525
| – | – | ﹤0.01% | 2044 |
|
|
2024
Q1 | $37K | Hold |
7,525
| – | – | ﹤0.01% | 2041 |
|
|
2023
Q4 | $66K | Hold |
7,525
| – | – | ﹤0.01% | 2019 |
|
|
2023
Q3 | $86K | Buy |
7,525
+4,300
| +133% | +$82.7K | ﹤0.01% | 1999 |
|
|
2023
Q2 | $82K | Sell |
3,225
-971
| -23% | -$30.2K | ﹤0.01% | 1947 |
|
|
2023
Q1 | $135K | Hold |
4,196
| – | – | ﹤0.01% | 1931 |
|
|
2022
Q4 | $78K | Buy |
4,196
+874
| +26% | +$20K | ﹤0.01% | 2022 |
|
|
2022
Q3 | $90K | Hold |
3,322
| – | – | ﹤0.01% | 2006 |
|
|
2022
Q2 | $46K | Hold |
3,322
| – | – | ﹤0.01% | 2074 |
|
|
2022
Q1 | $69K | Hold |
3,322
| – | – | ﹤0.01% | 2087 |
|
|
2021
Q4 | $54K | Hold |
3,322
| – | – | ﹤0.01% | 2152 |
|
|
2021
Q3 | $93K | Hold |
3,322
| – | – | ﹤0.01% | 2069 |
|
|
2021
Q2 | $98K | Hold |
3,322
| – | – | ﹤0.01% | 2091 |
|
|
2021
Q1 | $92K | Sell |
3,322
-1,456
| -30% | -$40.3K | ﹤0.01% | 2124 |
|
|
2020
Q4 | $135K | Buy |
4,778
+2,028
| +74% | +$52.5K | ﹤0.01% | 2049 |
|
|
2020
Q3 | $69K | Hold |
2,750
| – | – | ﹤0.01% | 2114 |
|
|
2020
Q2 | $67K | Hold |
2,750
| – | – | ﹤0.01% | 2151 |
|
|
2020
Q1 | $41K | Hold |
2,750
| – | – | ﹤0.01% | 2191 |
|
|
2019
Q4 | $44K | Buy |
+2,750
| New | +$42.6K | ﹤0.01% | 2309 |
|
|
2019
Q3 | – | Sell |
-5,183
| Closed | -$67K | – | 2362 |
|
|
2019
Q2 | $67K | Hold |
5,183
| – | – | ﹤0.01% | 2356 |
|
|
2019
Q1 | $81K | Buy |
5,183
+2,630
| +103% | +$45.6K | ﹤0.01% | 2130 |
|
|
2018
Q4 | $50K | Hold |
2,553
| – | – | ﹤0.01% | 2378 |
|
|
2018
Q3 | $63K | Hold |
2,553
| – | – | ﹤0.01% | 2336 |
|
|
2018
Q2 | $70K | Hold |
2,553
| – | – | ﹤0.01% | 2320 |
|
|
2018
Q1 | $79K | Hold |
2,553
| – | – | ﹤0.01% | 2241 |
|
|
2017
Q4 | $91K | Hold |
2,553
| – | – | ﹤0.01% | 2204 |
|
|
2017
Q3 | $69K | Hold |
2,553
| – | – | ﹤0.01% | 2251 |
|
|
2017
Q2 | $67K | Hold |
2,553
| – | – | ﹤0.01% | 2236 |
|
|
2017
Q1 | $53K | Hold |
2,553
| – | – | ﹤0.01% | 2289 |
|
|
2016
Q4 | $53K | Hold |
2,553
| – | – | ﹤0.01% | 2310 |
|
|
2016
Q3 | $41K | Hold |
2,553
| – | – | ﹤0.01% | 2371 |
|
|
2016
Q2 | $35K | Hold |
2,553
| – | – | ﹤0.01% | 2397 |
|
|
2016
Q1 | $45K | Hold |
2,553
| – | – | ﹤0.01% | 2177 |
|
|
2015
Q4 | $87K | Buy |
+2,553
| New | +$88.5K | ﹤0.01% | 1866 |
|
Other funds holding RVNC
Canada Life's RVNC Position: Q1 2025 in Review
Canada Life sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 7,525 shares — an estimated $23K sold.
Canada Life first reported a position in RVNC in Q4 2015 and held it in 36 quarters. The position peaked at $135K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Canada Life reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Canada Life sold 7,525 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $23K.
- Canada Life first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 36 quarters.
- Canada Life's Revance Therapeutics, Inc. position peaked at $135K in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Canada Life's 13F filing for Q1 2025, filed 15 May 2025.